Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin J Carroll

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Pharmaceutical Statistics|January 24, 2007
Analysis of progression-free survival in oncology trials: some common statistical issuesKevin J Carroll
Pharmaceutical Statistics|January 31, 2009
Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?Kevin J Carroll
Journal of Biopharmaceutical Statistics|August 21, 2013
Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?Kevin J Carroll
Controlled Clinical Trials|December 10, 2003
On the use and utility of the Weibull model in the analysis of survival dataKevin J Carroll
Pharmaceutical Statistics|November 28, 2006
Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?Kevin J Carroll
Pharmaceutical Statistics|March 14, 2007
Biomarkers in drug development: friend or foe? A personal reflection gained working within oncologyKevin J Carroll
Contemporary Clinical Trials|January 12, 2008
Analysis of duration of response in oncology trialsStuart Ellis, Kevin J Carroll, Kristine Pemberton
Pharmaceutical Statistics|April 3, 2024
A practical guide to the appropriate analysis of eGFR data over time: A simulation studyTodd DeVries, Kevin J Carroll, Sandra A Lewis
Pharmaceutical Statistics|May 5, 2017
Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case studyJohn Ouyang, Kevin J Carroll, Gary Koch, et al.
Pharmaceutical Statistics|November 3, 2023
Conditional power and information fraction calculations at an interim analysis for random coefficient modelsSandra A Lewis, Kevin J Carroll, Todd DeVries, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Pharmaceutical Statistics|January 24, 2007
Analysis of progression-free survival in oncology trials: some common statistical issuesKevin J Carroll
Pharmaceutical Statistics|January 31, 2009
Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?Kevin J Carroll
Journal of Biopharmaceutical Statistics|August 21, 2013
Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?Kevin J Carroll
Controlled Clinical Trials|December 10, 2003
On the use and utility of the Weibull model in the analysis of survival dataKevin J Carroll
Pharmaceutical Statistics|November 28, 2006
Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?Kevin J Carroll
Pharmaceutical Statistics|March 14, 2007
Biomarkers in drug development: friend or foe? A personal reflection gained working within oncologyKevin J Carroll
Contemporary Clinical Trials|January 12, 2008
Analysis of duration of response in oncology trialsStuart Ellis, Kevin J Carroll, Kristine Pemberton
Pharmaceutical Statistics|April 3, 2024
A practical guide to the appropriate analysis of eGFR data over time: A simulation studyTodd DeVries, Kevin J Carroll, Sandra A Lewis
Pharmaceutical Statistics|May 5, 2017
Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case studyJohn Ouyang, Kevin J Carroll, Gary Koch, et al.
Pharmaceutical Statistics|November 3, 2023
Conditional power and information fraction calculations at an interim analysis for random coefficient modelsSandra A Lewis, Kevin J Carroll, Todd DeVries, et al.
Pageof 3